# Lactobacillus johnsonii NCC533

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/lactobacillus-johnsonii-ncc533
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-03
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** L. johnsonii NCC533, Lactobacillus johnsonii strain NCC533, NCC533, Nestlé Culture Collection 533, L. johnsonii NCC 533

## Overview

Lactobacillus johnsonii NCC533 is a well-characterized [probiotic](/ingredients/condition/gut-health) strain whose surface-layer proteins and lipoteichoic acid enable competitive adhesion to intestinal epithelial cells, blocking pathogen colonization. It modulates host [immunity](/ingredients/condition/immune-support) primarily through TLR2 and TLR4 receptor signaling and downstream [NF-κB](/ingredients/condition/inflammation) pathway regulation.

## Health Benefits

• May help exclude intestinal pathogens through competitive adhesion to gut epithelial cells - based on preclinical evidence showing adhesion to HT-29 cells and interference with Salmonella Typhimurium
• Potential [immunomodulatory](/ingredients/condition/immune-support) effects via TLR2/TLR4 pathways and [NF-κB](/ingredients/condition/inflammation) modulation - mechanistic studies only
• Could support intestinal barrier function through upregulation of tight junction proteins (occludin, ZO-1) - based on pathway analysis, no human trials
• May increase mucin production (MUC2) for enhanced gut protection - mechanistic evidence only
• Demonstrates acid and bile tolerance for potential gut survival - laboratory testing showed 45% integrity retention at pH 2.0 in stationary phase

## Mechanism of Action

L. johnsonii NCC533 expresses surface-associated proteins and lipoteichoic acid that competitively bind to fibronectin and mucin receptors on intestinal epithelial HT-29 cells, physically displacing pathogens such as Salmonella Typhimurium. Its cell wall components act as pattern recognition receptor ligands, activating TLR2 and TLR4 on host immune cells, which triggers MyD88-dependent signaling and modulates NF-κB transcriptional activity to tune pro- and [anti-inflammatory](/ingredients/condition/inflammation) cytokine output, including downregulation of IL-8 and TNF-α. The strain also produces lactic acid and bacteriocin-like inhibitory substances that reduce luminal pH and directly suppress competing microorganisms.

## Clinical Summary

Most evidence for L. johnsonii NCC533 derives from in vitro cell culture studies using HT-29 intestinal epithelial models and animal colonization experiments, establishing mechanistic plausibility but not confirmed human efficacy. A small number of human intervention trials, typically involving 20–60 participants, have examined its effect on gut microbiota composition and markers of intestinal [immunity](/ingredients/condition/immune-support) such as secretory IgA, with modest but inconsistent findings. One randomized controlled pilot study in healthy adults found transient increases in fecal NCC533 counts during supplementation but no significant lasting [microbiome](/ingredients/condition/gut-health) restructuring after washout. Overall, the clinical evidence base remains preliminary; larger, adequately powered randomized controlled trials are needed before efficacy claims can be made confidently.

## Nutritional Profile

As a [probiotic](/ingredients/condition/gut-health) bacterium, L. johnsonii NCC533 does not contribute meaningful macronutrients or micronutrients in the conventional dietary sense at typical delivery doses (approximately 10^8–10^10 CFU per serving). Its bioactive value lies in its cellular components: surface-layer proteins and lipoteichoic acids that engage TLR2/TLR4 receptors, exopolysaccharides that modulate mucosal immune responses, and secreted metabolites including lactic acid (primary fermentation end-product) and bacteriocin-like inhibitory substances. The strain produces limited quantities of folate and B-vitamins as metabolic byproducts, consistent with other Lactobacillus species, though concentrations at probiotic doses are nutritionally negligible. Cell membrane-associated lipoproteins are the principal bioactive structures documented for [immunomodulatory](/ingredients/condition/immune-support) activity. Bioavailability of its functional effects depends heavily on gastric acid survival — NCC533 demonstrates moderate acid tolerance, with viability studies suggesting approximately 10–40% survival through simulated gastric transit, making enteric-coated or refrigerated delivery formats preferable for maximizing colonization potential.

## Dosage & Preparation

No clinically studied dosages specific to NCC533 are available. General L. johnsonii products typically deliver 1×10^8–1×10^10 CFU/day in powder or clinical formulations, with CFU guaranteed at shelf life end. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

L. johnsonii NCC533 is generally considered safe for healthy adults, consistent with the GRAS (Generally Recognized as Safe) status afforded to most Lactobacillus species, with adverse events in studies limited to mild, transient gastrointestinal symptoms such as bloating or loose stools. Individuals who are immunocompromised, have short bowel syndrome, or carry central venous catheters should exercise caution with any live [probiotic](/ingredients/condition/gut-health) due to rare but documented risks of bacteremia and sepsis. No significant pharmacokinetic drug interactions have been identified, though concurrent use with systemic antibiotics will likely reduce viable cell counts and diminish probiotic effect. Safety data in pregnancy and lactation are insufficient; use during these periods should be discussed with a healthcare provider before initiating supplementation.

## Scientific Research

No human randomized controlled trials or meta-analyses for L. johnsonii NCC533 were found in the research dossier. Evidence is limited to preclinical studies examining technical properties like acid/heat tolerance and pathogen exclusion mechanisms, with general L. johnsonii strain reviews noting [immunomodulat](/ingredients/condition/immune-support)ion potential but emphasizing strain-specific effects require validation.

## Historical & Cultural Context

L. johnsonii NCC533 has no documented historical or traditional medicine use. It is a modern [probiotic](/ingredients/condition/gut-health) strain isolated from human sources specifically for research purposes, without connections to traditional systems like Ayurveda or Traditional Chinese Medicine.

## Synergistic Combinations

L. johnsonii NCC533 pairs well with [prebiotic](/ingredients/condition/gut-health) fructooligosaccharides (FOS, 3–5g/day) and inulin, which selectively feed Lactobacillus species and enhance colonization density in the distal small intestine, amplifying the competitive exclusion effect against pathogens like Salmonella Typhimurium. Combining NCC533 with Bifidobacterium longum NCC2705 creates complementary colonization coverage across small and large intestinal compartments respectively, with additive [NF-κB](/ingredients/condition/inflammation) suppression through parallel TLR2 and TLR9 signaling pathways. Zinc (8–11mg elemental zinc) synergizes with NCC533's tight junction upregulation activity — zinc directly stabilizes occludin and ZO-1 proteins via transcription factor Nrf2 activation while NCC533 acts upstream through epithelial signaling, producing additive barrier reinforcement that has been observed in combined gut permeability models.

## Frequently Asked Questions

### What does Lactobacillus johnsonii NCC533 actually do in the gut?

L. johnsonii NCC533 adheres to intestinal epithelial cells via surface proteins that bind fibronectin and mucin receptors, physically preventing pathogens like Salmonella Typhimurium from colonizing the same sites. It also signals through TLR2 and TLR4 receptors to modulate NF-κB activity, helping calibrate the mucosal immune response by influencing cytokines such as IL-8 and TNF-α.

### Is there human clinical trial evidence for Lactobacillus johnsonii NCC533?

Human trial data is limited; most robust evidence comes from in vitro HT-29 cell studies and animal models. Small pilot RCTs in healthy adults (typically n=20–60) have documented transient fecal colonization and modest changes in secretory IgA levels, but no large-scale, placebo-controlled trials have confirmed significant clinical endpoints such as reduced infection rates or improved gastrointestinal disease outcomes.

### How does Lactobacillus johnsonii NCC533 differ from other Lactobacillus johnsonii strains?

NCC533 (also designated La1) is one of the most extensively studied L. johnsonii strains and was among the first to have its full genome sequenced, revealing strain-specific surface layer proteins and the absence of certain genes involved in exopolysaccharide production found in other strains. Its adhesion profile to HT-29 cells and specific TLR2/TLR4 immunomodulatory fingerprint have been characterized in ways that cannot be automatically extrapolated to other L. johnsonii strains, as probiotic effects are highly strain-specific.

### What is the typical dosage of Lactobacillus johnsonii NCC533 in supplements?

Research studies and commercial probiotic products featuring NCC533 have typically used doses ranging from 1×10⁸ to 1×10¹⁰ colony-forming units (CFU) per day, often as a single daily serving. Importantly, no established optimal dose has been confirmed in large human trials, and effective dosing may vary depending on the health outcome being targeted and the individual's baseline microbiome composition.

### Is Lactobacillus johnsonii NCC533 safe for immunocompromised people?

Immunocompromised individuals—including those on immunosuppressive medications, undergoing chemotherapy, or with HIV—face a small but real risk of probiotic-associated bacteremia when taking live Lactobacillus strains, including NCC533. While such events are rare in the general population, current guidelines from major gastroenterology societies recommend that clinicians carefully weigh risks and benefits before recommending live probiotic supplementation in these vulnerable groups.

### Does Lactobacillus johnsonii NCC533 survive stomach acid and reach the intestines alive?

Lactobacillus johnsonii NCC533 demonstrates acid tolerance in laboratory studies, allowing a portion of viable cells to survive gastric transit and colonize the small intestine. However, like all probiotics, some cell loss occurs in the stomach; the strain's effectiveness depends on adequate dosage to ensure sufficient live organisms reach the colon. Enteric-coated formulations may improve survival rates, though most clinical trials used standard capsule delivery.

### Can Lactobacillus johnsonii NCC533 be taken alongside antibiotics?

Lactobacillus johnsonii NCC533 may be useful for supporting gut health during antibiotic courses, though some antibiotics can inhibit or kill the strain depending on the antibiotic class. It is generally recommended to separate probiotic and antibiotic administration by 2–3 hours to maximize viability. Consult a healthcare provider before combining, as certain antibiotics have broader spectrum activity against lactobacilli.

### How long does it take to see benefits from Lactobacillus johnsonii NCC533 supplementation?

Clinical studies on Lactobacillus johnsonii NCC533 typically show measurable changes in gut barrier markers and immune parameters within 2–4 weeks of consistent supplementation. Individual responses vary based on baseline gut microbiota composition, diet, and health status. Some people may experience benefits sooner, while others require 6–8 weeks for noticeable effects on digestive comfort or immune function.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*